Key Findings:  The neuro-modulatory actions at CB1 receptors by endocannabinoids, of which anandamide and 2-arachidonoylglycerol are the two most studied representatives, allows them to counteract the neuro-chemical imbalances arising during Alzheimer’s disease, multiple sclerosis, amyotropic lateral sclerosis, Parkinson’s disease, and Huntington’s chorea.
Type of Study:  Meta-analysis
Study Result:  Positive
Cannabinoids Studied:  Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source:  Not Applicable